Incyte (INCY) Gross Profit Growth (1y) (2013 - 2026)

Incyte (INCY) Gross Profit Growth (1y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Profit Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 41.37%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 7.76%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 16.94%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 68.41%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Incyte 23.64 Bn 19.62 Bn 1.17 Bn 19.23%

Historic Data

Download Data
DateValue
Mar 31, 2026 19.23%
Dec 31, 2025 27.10%
Sep 30, 2025 20.45%
Jun 30, 2025 17.54%
Mar 31, 2025 19.49%
Dec 31, 2024 15.54%
Sep 30, 2024 22.46%
Jun 30, 2024 9.12%
Mar 31, 2024 9.06%
Dec 31, 2023 8.77%
Sep 30, 2023 11.74%
Jun 30, 2023 2.97%
Mar 31, 2023 8.87%
Dec 31, 2022 5.93%
Sep 30, 2022 -0.57%
Jun 30, 2022 28.92%
Mar 31, 2022 20.00%
Dec 31, 2021 8.74%
Sep 30, 2021 31.86%
Jun 30, 2021 1.99%